Ivermectin as a Novel Therapy in COVID-19 Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04403555 |
Recruitment Status :
Completed
First Posted : May 27, 2020
Last Update Posted : August 2, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID | Drug: Ivermectin | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 164 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Efficacy of Ivermectin in COVID-19 Treatment |
Actual Study Start Date : | June 1, 2020 |
Actual Primary Completion Date : | October 31, 2020 |
Actual Study Completion Date : | December 1, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Ivermectin
Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days
|
Drug: Ivermectin
Ivermectin treatment
Other Name: iverzine, ivermectin |
No Intervention: Standard of care
Standard of care treatment
|
- The number of patients with mortality [ Time Frame: 1 month ]Improvement of survival
- Length of hospital stay [ Time Frame: 1 month ]Effect on the length of hospital stay
- The need for mechanical ventilation [ Time Frame: 1 month ]Need for mechanical ventilation

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All Adult Patients aging from 20 to 65 years-old with COVID-19 confirmed by pharyngeal swab PCR.
Exclusion Criteria:
- Allergy or contraindication to the drugs used in the study.
- Pregnant and lactating mothers.
- Patients with cardiac problems.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04403555
Egypt | |
Sherief Abd-Elsalam | |
Tanta, Egypt |
Principal Investigator: | sherief Abd-Elsalam, Ass. Prof. | ass. Prof. Tropical Medicine |
Responsible Party: | Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University |
ClinicalTrials.gov Identifier: | NCT04403555 |
Other Study ID Numbers: |
tanta covid treatment |
First Posted: | May 27, 2020 Key Record Dates |
Last Update Posted: | August 2, 2021 |
Last Verified: | July 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Ivermectin Antiparasitic Agents Anti-Infective Agents |